These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 4035363)

  • 1. Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractions.
    Emanuele RM; Fareed J; Walenga JM; Hoppensteadt DA; Baker WH
    Semin Thromb Hemost; 1985 Apr; 11(2):121-8. PubMed ID: 4035363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions.
    Fareed J; Kumar A; Rock A; Walenga JM; Davis P
    Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.
    Fareed J; Walenga JM; Williamson K; Emanuele RM; Kumar A; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):56-74. PubMed ID: 3883500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].
    Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G
    Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A.
    Amiral J; Walenga JM; Fareed J
    Semin Thromb Hemost; 1984 Oct; 10(4):228-42. PubMed ID: 6393350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide.
    Walenga JM; Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):89-99. PubMed ID: 4035370
    [No Abstract]   [Full Text] [Related]  

  • 8. The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.
    Nossel HL; Ti M; Kaplan KL; Spanondis K; Soland T; Butler VP
    J Clin Invest; 1976 Nov; 58(5):1136-44. PubMed ID: 993337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis.
    Wilhelmsson S; Asaba H; Gunnarsson B; Kudryk B; Robinson D; Bergström J
    Clin Nephrol; 1981 May; 15(5):252-8. PubMed ID: 7249422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169).
    Walenga JM; Fareed J; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):17-25. PubMed ID: 3883497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions.
    Hoppensteadt DA; Walenga JM; Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):112-20. PubMed ID: 3898369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
    Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR
    Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation.
    Ireland HA; Boisclair MD; Lane DA; Thompson E; Curtis JR
    Clin Nephrol; 1991 Jan; 35(1):26-33. PubMed ID: 1826095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J
    J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
    Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
    Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of heparin fractions: old vs. new methods.
    Walenga JM; Fareed J; Hoppensteadt D; Emanuele RM
    Crit Rev Clin Lab Sci; 1986; 22(4):361-89. PubMed ID: 2936571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels.
    Edwards RL; Klaus M; Matthews E; McCullen C; Bona RD; Rickles FR
    Am J Med; 1990 Jul; 89(1):25-8. PubMed ID: 2368789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A low molecular heparin fraction as an anticoagulant during hemodialysis.
    Ljungberg B
    Clin Nephrol; 1985 Jul; 24(1):15-20. PubMed ID: 4017295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fibrinogen metabolism and plasma fibrinopeptide A in disseminated neoplasms].
    Mombelli G; Roux A; Hofmann V; Straub PW
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1901. PubMed ID: 531571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.